19:33-40.
[0130] 5. Beck NB, Sidhu JS，Omiecinski CJ. Baculovirus vectors repress phenobarbital-mediated gene induction and stimulate cytokine expression in primary cultures of rat hepatocytes.(在大鼠肝細(xì)胞的原代培養(yǎng)物中桿狀病毒載體抑 制苯巴比妥介導(dǎo)的基因誘導(dǎo)并激活細(xì)胞因子表達(dá)）Gene Ther 2000;7:1274-83.
[0131] 6. Bessis Nj GarciaCozar F，Boissier M. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms.(針對(duì)基因治療載體 的免疫應(yīng)答：對(duì)載體功能和效應(yīng)機(jī)制的影響）Gene Therapy 2004 ;l:S10-7.
[0132] 7. Boulaire J，Zhao Y，Wang S. Gene expression profiling to define host response to baculoviral transduction in the brain.(定義大腦中宿主對(duì)桿狀病毒轉(zhuǎn) 導(dǎo)應(yīng)答的基因表達(dá)概況）J Neurochem 2009;109:1203-14.
[0133] 8. Burke J. Virus therapy for bladder cancer.(用于膀脫癌的病毒治療） Cytokine Growth Factor Rev. 2010 年 4-6 月；21 (2-3) :99-102.
[0134] 9. Calcedo R，Vandenberghe LH，Gao G，等，Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.(針對(duì)腺相關(guān)病毒中和抗體的 全球流行病學(xué)）J Infect Dis 2009;199:381-90.
[0135] 10. Chen GY，Shiah HCj Su HJj 等，Baculovirus transduction of mesenchymal stem cells triggers the toll-like receptor 3pathway.(間充質(zhì)干細(xì)胞的桿狀病毒轉(zhuǎn) 導(dǎo)引發(fā) toll 樣受體 3 通路）J Virol 2009 ;83:10548-56.
[0136] 11. Chiong Ej Esuvaranathan K. New therapies for non-muscle-invasive bladder cancer.(非肌肉侵入性膀胱癌的新療法）World J Urol. 2010年2月； 28(1) :71-8.
[0137] 12.Cross D，Burmester J. Gene therapy for cancer treatment: past, present and future.(癌癥治療的基因治療：過(guò)去、現(xiàn)在和未來(lái)）Clin Med Res 2006 ;4:218-27.
[0138] 13. Dumey NjMongiat-Artus PjDevauchelle PjLesourd AjCotard JPjLe Due A,Marty M，Cussenot 0,Cohen-Haguenauer 0.1 n vivo retroviral mediated gene transfer into bladder urothelium results in preferential transduction of tumoral cells.(體內(nèi)逆轉(zhuǎn)錄病毒介導(dǎo)的至膀胱上皮的基因轉(zhuǎn)移導(dǎo)致腫瘤細(xì)胞的優(yōu)先轉(zhuǎn) 導(dǎo)）Eur Urol. 2005 年 2 月；47 (2) : 257-63.
[0139] 14. Fodor I, Timiryasova Tj Denes B，Yoshida J，Ruckle Hj Lilly M. Vaccinia virus mediated p53gene therapy for bladder cancer in an orthotopic murine model.(原位鼠模型中針對(duì)膀胱癌的疫苗病毒介導(dǎo)的p53基因治療）J Urol. 2005年2月； 173(2) :604-9.
[0140] 15. Gomella LG，Mastrangelo MJ，McCue PA, Maguire HC JR，Mulholland SG, Lattime EC. Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer.(用作膀胱癌基因治療載體的膀胱內(nèi)疫苗病毒的I期研究）J Urol. 2001 年 10 月；166(4):1291-5.
[0141] 16. Gronowski AM，Hilbert DM，Sheehan KC，等，Baculovirus stimulates antiviral effects in mammalian cells.(哺乳動(dòng)物細(xì)胞中桿狀病毒激活抗病毒作用）J Virol 1999;73:9944-51.
[0142] 17. Gunther JHjJurczok AjWulf TjBrandau SjDeinert IjJocham Dj Bohle A. Optimizing syngeneic orthotopic murinebladder cancer (MB49) ·(優(yōu)化同源原位鼠膀 胱癌（MB49)) Cancer Res. 1999 年 6 月 15 日；59 (12) :2834-7.
[0143] 18. Hacein-Bey-Abina S，Von Kalle C，Schmidt M，等，LM02_associated clonal T cell proliferation in two patients after gene therapy for SCID-XL (SCID-X1基 因治療后兩名患者中LM02相關(guān)的克隆T細(xì)胞增殖）Science 2003 ;302:415-9.
[0144] 19. Hadaschik BA, Zhang K，So Al, Fazli L，Jia W，Bell JC，Gleave ME，Rennie PS. Oncolytic vesicularstomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.(溶瘤水泡性口炎病毒是高風(fēng)險(xiǎn)膀胱癌的膀胱 內(nèi)治療的有效試劑）Cancer Res. 2008 年6 月 15 日；68(12) :4506-10.
[0145] 20. Hanel EGjXiao ZjWong KKjLee PWjBritten RAjMoore RB. A novel intravesical therapy for superficial bladder cancer in an orthotopic model:oncolytic reovirus therapy.(原位模型中淺表性膀胱癌的全新膀胱內(nèi)療法：溶瘤 反轉(zhuǎn)錄病毒療法）J Urol.2004 年 11 月；172(5Pt 1):2018-22.
[0146] 21. Hervas-Stubbs Sj Rueda Pj Lopez L，等，Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN(由 I 型 IFN誘導(dǎo)的昆 蟲(chóng)桿狀病毒增強(qiáng)適應(yīng)性免疫應(yīng)答）.J Immunol 2007;178:2361-9.
[0147] 22. Hofmann C，Sandig V，Jennings G，等，Efficient gene transfer into human hepatocytes by baculovirus vectors.(通過(guò)桿狀病毒載體的至人干細(xì)胞的有效基因轉(zhuǎn) 移）Proc Natl Acad Sci U S A 1995 ;92:10099-103.
[0148] 23. Hofmann Cj Hliser A，Lehnert Wj 等，Protection of baculovirus-vectors against complement-mediated inactivation by recombinant soluble complement receptor type 1.(桿狀病毒載體對(duì)重組可溶補(bǔ)體受體I型所致補(bǔ)體介導(dǎo)失活的保護(hù)） Biol Chem 1999 ;380:393-5.
[0149] 24. Hu YC. Baculoviral vectors for gene delivery:a review.(用于基因遞送 的桿狀病毒載體：綜述）Curr Gene Ther 2008;8:54-65.
[0150] 25. Hu YC. Baculovirus:a promising vector for gene therapy ?(桿狀病毒： 有希望的基因治療載體？）Curr Gene Ther.2010年6月；10(3):167.
[0151] 26. Huang X，Yang Y.Innate immune recognition of viruses and viral vectors.(病毒和病毒載體的先天免疫識(shí)別）Hum Gene Ther 2009;20:293-301.
[0152] 27. Kikuchi EjMenendez SjOzu CjOhori MjCordon-Cardo CjLogg CRjKasahara N，Bochner BH.Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.(膀月光內(nèi)給 予復(fù)制有效的反轉(zhuǎn)錄病毒載體產(chǎn)生的膀胱癌的高效基因遞送）Clin Cancer Res. 2007年8 月 1 日；13(15Pt I) :4511-8.
[0153] 28. Kikuchi Ej Menendez Sj Ohori Mj Cordon-Cardo C，Kasahara Nj Bochner BH. Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin.(內(nèi)皮抑素的慢病毒基因轉(zhuǎn)移對(duì)原位人膀胱腫瘤生長(zhǎng)的抑制） Clin Cancer Res. 2004 年 3 月 1 日；10(5):1835-42.
[0154] 29. Kimura TjOhashi TjKikuchi TjKiyota HjEto YjOhishi Y. Antitumor immunity against bladder cancer induced by ex vivo expression of CD40ligand gene using retrovirus vector.(使用逆轉(zhuǎn)錄病毒載體離體表達(dá)⑶40配體基因誘導(dǎo)的針 對(duì)膀胱癌的抗腫瘤免疫）Cancer Gene Ther. 2003年11月；10(11) :833-9.
[0155] 30. Kitajima Mj Abe Tj Miyano-Kurosaki N，Taniguchi Mj Nakayama T，Takaku H. Induction of natural killer cell-dependent antitumor immunity by the Autographa californica multiple nuclear polyhedrosis virus.(苜蓿銀紋夜蛾多重 核型多角體病毒感染所致天然殺傷細(xì)胞依賴的抗腫瘤免疫的誘導(dǎo)）Mol Ther. 2008年2月； 16(2) :261-8.
[0156] 31.Kitajima M，Takaku H. Induction of antitumor acquired immunity by baculovirus Autographa californica multiple nuclear polyhedrosis virus infection in mice.(小鼠桿狀病毒苜蓿銀紋夜蛾多重核型多角體病毒感染所致抗腫瘤獲 得性免疫的誘導(dǎo)）Clin Vaccine Immunol 2008b ;15:376_8·
[0157] 32.Kost TA,Condreay JPj Jarvis DL. Baculovirus as versatile vectors for protein expression in insect and mammalian cells.(作為用于昆蟲(chóng)和哺乳動(dòng)物細(xì)胞中 蛋白表達(dá)的多功能載體的桿狀病毒）Nat Biotechnol 2005;23:567-75.
[0158]